The Potential Role of CDH1 as an Oncogene Combined With Related miRNAs and Their Diagnostic Value in Breast Cancer

Dan Xie†, Yiyu Chen†, Xue Wan†, Jingyuan Li, Qin Pei, Yanan Luo, Jinbo Liu and Ting Ye*

Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan, China

Background: Breast cancer (BC) is the leading cause of cancer–related mortality in females and the most common malignancy with high morbidity worldwide. It is imperative to develop new biomarkers and therapeutic targets for early diagnosis and effective treatment in BC.

Methods: We revealed the oncogene function of cadherin 1 (CDH1) via bioinformatic analysis in BC. Moreover, miRNA database was utilized to predict miRNAs upstream of CDH1. Expression of CDH1-related miRNAs in BC and their values in BC stemness and prognosis were analyzed through TCGA-BRCA datasets. In addition, Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) were performed to explore the potential functions and signaling pathways of CDH1 in combination with CDH1-related miRNAs in BC progression. Finally, the differential expressions of soluble E-cadherin (sE-cad), which is formed by the secretion of CDH1-encoded E-cadherin into serum, analyzed by enzyme-linked immunosorbent assay (ELISA). Reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) was used to detect the expression level of CDH1-related miRNAs in serum samples.

Results: The mRNA and protein expressions of CDH1 were elevated in BC tissues compared with normal counterparts. Moreover, CDH1 overexpression was positively correlated with BC stage, metastatic, stemness characteristics, and poor prognosis among patients. In predictive analysis, miR-340, miR-185, and miR-20a target CDH1 and are highly expressed in BC. miR-20a overexpression alone was strongly associated with high stemness characteristics and poor prognosis of BC. Additionally, GO, KEGG, and hallmark effect gene set analysis demonstrated that CDH1 in combination with overexpression of miR-340, miR-185, or miR-20a participated in multiple biological processes and underly signaling pathways involving in tumorigenesis and development of BC. Finally, we provide experimental evidence that the combined determination of serum sE-cad and miR-20a in BC has highly diagnostic efficiency.
INTRODUCTION

Breast cancer (BC) is the leading cause of cancer–related mortality in females and the most common malignancy with high morbidity worldwide (1). Despite of diagnosis and therapeutic predominant advancements of BC, its treatment efficacy and prognosis have not been substantially improved, generally attributed to late diagnosis and tumor metastasis (2, 3). Therefore, it is imperative to develop new biomarkers and therapeutic targets for early diagnosis and effective treatment in BC. Furthermore, a growing body of evidence indicates that cancer stem cells (CSCs, also known as tumor-initiating cells or tumor-propagating cells) are a small subpopulation of cells with self-renewal capability and differentiation potential, which are considered to be the root of cancer initiation, metastasis, treatment resistance, and poor prognosis (4, 5). Therefore, identifying gene signatures associated with the characteristics of CSCs has diagnostic and prognostic implications.

The CDH1 gene encodes E-cadherin (E-cad) protein, a calcium-dependent transmembrane adhesion that is crucial for maintaining pluripotency and self-renewal of embryonic stem cells and neural stem cells (6–8). CDH1 is commonly reported as a tumor suppressor gene in cancer literature (9). Downregulation or loss of E-cad encoded by CDH1 is also known to contribute to malignant tumor invasion and metastasis (10–12). Recent studies have demonstrated that CDH1 and its encoded E-cad have oncogenic properties. CDH1 oncogene, for example, induces self-renewal of lung cancer stem-like cells (13). E-cad+ subsets of prostate cancer cells displayed characteristics associated with cancer stem cells, and prostate cancer stem cells exhibit the plasticity of E-cad expression during cell invasion (14, 15). In BC, high expression of E-cad in SKBR3 cells was allowed to enhance mammosphere formation (16). Moreover, Padmanaban et al. (17) demonstrated that E-cad promotes metastasis in murine and human models of both luminal and basal-like breast cancer. In addition to above observations, a reported study has revealed that even though E-cad is a transmembrane molecule, its extracellular structure can be cleaved off and released into the bloodstream in the soluble form, also known as soluble E-cadherin (sE-cad) (18). Numerous publications have discussed sE-cad, which is highly expressed in the serum of patients with malignant tumors, as a diagnostic and prognostic biomarker of malignancy (19–22). The serum level of sE-cad in lung cancer patients was significantly higher than in control subjects, and patients with distant metastasis had an even more significant increase (21). The high serum sE-cad level was also found to positively correlate with TNM stage, tumor grade, and lymph node metastasis in BC (22). These results demonstrated that the tumor suppressor or pro-oncogene role of CDH1 in malignant tumors is controversial and has not been well elucidated.

MicroRNAs (miRNAs) are noncoding RNAs that regulate gene expression by identifying cognate sequences and interfering with transcription, translation, and epigenetic processes (23). Several miRNAs can be oncogenes or tumor suppressors, and their dysregulation leads to cancer initiation, progression, and metastasis (24). Furthermore, miRNAs can be secreted into the bloodstream and remain highly stable in serum or plasma (25). As a result, circulating miRNAs are considered ideal tumor biomarkers. miRNAs in serum or plasma are increasingly recognized as molecular markers for non-invasive diagnosis and prognosis of cancer (26). For example, serum miR-103a-3p could serve as a potential non-invasive diagnostic and prognostic biomarker for BC (27). In prostate cancer, the higher levels of miR-1290 and miR-375 were significantly associated with poorer overall survival (28).

Bioinformatics analysis of Oncomine, TIMER, TCGA, GEO and GEPIA databases in the present study revealed that CDH1 may function not only as a tumor suppressor but also as a pro-oncogene capable of accelerating the malignant progression of BC. In predictive analysis, miR-340, miR-185, and miR-20a target CDH1 and are highly expressed in BC. GO, KEGG and hallmark gene set analyzes were then used to investigate the potential functions and signaling pathways of CDH1 in combination with overexpression of miR-340, miR-185, or miR-20a in BC. This suggests that these miRNAs could regulate CDH1’s oncogenic mechanisms. Finally, we provide experimental evidence that combined determination of serum sE-cad and miR-20a in BC has high diagnostic efficiency. The results of this study reveal a novel role for CDH1 and miRNAs that regulate it as BC pro-oncogenes, and suggest that serum sE-cad and miR-20a are potentially noninvasive diagnostic markers for BC.

MATERIALS AND METHODS

Oncomine Analysis

Oncomine (http://www.oncomine.org/), a web-based cancer microarray database, is used to compare the transcriptome data in most major types of cancer with respective normal tissues (29). The gene expression levels of CDH1 in BC was identified in Oncomine.

TIMER2.0 Database Analysis

TIMER2.0 (http://timer.comp-genomics.org/) is a tumor related database (30). Timer algorithms to learn about the differences of CDH1 expressions was performed using TIMER2.0.

Conclusions: This study provides evidence for CDH1 as an oncogene in BC and suggests that miR-20a may regulate the stemness characteristics of BC to exert a pro-oncogenic effect by regulating CDH1. Moreover, sE-cad and miR-20a in serum can both be used as valid noninvasive markers for BC diagnosis.

Keywords: CDH1, miRNAs, oncogene, breast cancer, biomarker
The Cancer Genome Atlas (TCGA) Dataset Analysis
Gene expression profile for BC cancer patients was obtained from TCGA data portal (https://portal.gdc.cancer.gov/) (31). Clinical data such as gender, age, histological type, and survival were also downloaded from TCGA data portal. The original data from TCGA was normalized and analyzed by R language.

GEO Datasets Selecting and Differential Analysis
The two gene expression datasets of BC from GEO database were downloaded, including the following criterias: (a) BC, (b) datasets including tumor and normal tissues, (c) the organism is Homo sapiens, (d) sample size exceeding 30 samples. GSE45255 and GSE2603 were among depended on the GPL90 platform (32). The limma package was used to identify the DEGs in each GEO datasets in R. The P-value is determined by the false discovery rate.

Gene Expression Profiling Interactive Analysis (GEPIA) Database Analysis
The online database GEPIA (http://geopia2.cancer-pku.cn/index) is a web-based database that includes 9,736 tumors and 8,587 normal samples, which analyze the RNA sequencing expression between the tumor and normal tissue (33). GEPIA was used to further confirm the differential expression of genes.

Human Protein Atlas Analysis (HPA) Analysis
HPA (https://www.proteinatlas.org/) makes use of antibody method for immunostaining on differential expression analysis of proteins in normal and tumor tissues (34). We checked the expression of CDH1 in the protein expression module of the HPA database and analyzed the immunohistochemical results of CDH1 in tumor tissues and normal tissues (Antibody: CAB072856).

Immunohistochemical Staining
The paraffin-embedded tissues were collected from the Pathology Department of the Affiliated Hospital of Southwest Medical University. The tissue slides were then deparaffinized, rehydrated, and stained overnight at 4°C with a 1:500 dilution of the rabbit polyclonal E-cadherin antibody (208741AP, Proteintech). Moreover, the slides were incubated with streptavidin horseradish peroxidase (HRP) after being treated with biotinylated secondary antibody. Finally, they were stained with 3', 3'-Diaminobenzidine (DAB) and haematoxylin counterstained. Immunostaining intensity was graded as follows: 1 mild (+), 2 moderate (++), and 3 high (+++).

Kaplan-Meier Plotter Database
The prognostic significance of mRNA expression in BC cancer was evaluated using the Kaplan-Meier plotter (www.kmplot.com) (35). The overall survival (OS), distant metastasis-free survival (DMFS), and recurrence-free survival (RFS) of BC cancer patients were analyzed by the Kaplan-Meier survival plot.

Calculation of the Gene Expression-Based Stemness Index (mRNAsi)
The one-class logistic regression (OCLR) algorithm was used to calculate the stemness index based on gene expression profiles of normal PSCs (36). The stemness signature was generated with the OCLR algorithm by utilizing the gelnet package in R. Then, we calculated the Spearman correlations between the weight vectors of the stemness signature and mRNA expressions of BC samples. The stemness index generated from gene expression profiles was defined as mRNAsi.

Pearson’s Correlation Analysis
The co-expression analysis was constructed using R to show Pearson correlation coefficient between two genes.

Gene Set Enrichment Analysis (GSEA)
GSEA was carried out between datasets with high or low CDH1 and micro-RNAs mRNA expression (37). The Hallmark effector gene sets and the Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway associated with CDH1 and micro-RNAs mRNA expression were annotated. GSEA software was obtained from the Broad Institute (http://www.broad.mit.edu/gsea).

Analyses of miRNA-mRNA Targets
In order to predict miRNAs upstream of CDH1, we used the StarBase (http://starbase.sysu.edu.cn/), miRDB (http://www.mirdb.org/), miRWalk (http://mirwalk.umm.uni-heidelberg.de/), microRNA (www.microrna.org/), and TargetsCan (http://www.targetscan.org/) to locate the potential miRNAs targeting CDH1.

The Analysis of Diagnostic Efficiency
The receiver operating characteristic (ROC) curve was used to illustrate the diagnostic efficiency of CDH1, microRNAs, and sE-cad.

Clinical Samples
The patient’s consent was obtained according to the protocol approved by the Institutional Review Committee of the Affiliated Hospital of Southwest Medical University. All samples were obtained from the Department of Medical Laboratory, Affiliated Hospital of Southwest Medical University. A total of 100 serum samples were collected, including 50 healthy controls and 50 patients with pathological diagnosis of BC. Each patient with BC was classified according to AJCC Cancer Staging Manual.

Isolation of miRNAs From Serum
According to the manufacturer’s protocol, total RNA was extracted from serum (volume, 200 µl) using a miRcute miRNA extraction isolation kit (DP501, Tiangen, China). These RNAs were then reverse-transcribed into cDNA using the instructions of All-in-OneTM miRNA qRT-PCR kit (GeneCopoeia, the US).
High Expression of CDH1 in BC Patients
We first compared the mRNA levels of CDH1 in 21 types of cancers with their normal counterparts by using TIMER2.0 database. CDH1 mRNA expression was increased in 11 types of cancers, decreased in 4 types of cancers, and there was no significant difference in 6 types of cancers (Figure 1A). These findings revealed that increased mRNA expression of CDH1 is a rather common feature of human cancer that currently merits highly appreciated. Meanwhile, we conducted in-depth analysis in BC by other public databases. We initially analyzed CDH1 transcription levels in BC tissues in Oncomine and found that CDH1 was expressed at a higher level in BC tissues compared to normal tissues. CDH1 was highly expressed in several BC subtypes, including Luminal A, Luminal B, HER2+ and TNBC. GSEA enrichment analysis revealed that CDH1 overexpression is positively associated with Metastasis Status (Figure 2B). As shown in Figure 2B, CDH1 expression in patients with advanced stages (III-IV) was significantly higher than in those with early stages (I-II). Likewise, the markedly differences occur between the metastatic and non-metastatic patients (Figure 2C). Then, the Kaplan-Meier plotter tool was used to explore the correlation between CDH1 expression and clinical outcomes in BC. BC patients with CDH1 overexpression showed worse overall survival (OS) [HR = 1.81, \( P = 0.034 \)], distant metastasis-free survival (DMFS) [HR = 1.75, \( P = 0.025 \)] and relapse-free survival (RFS) [HR = 2.09, \( P = 0.0022 \)] than patients with minimal expression of CDH1 (Figure 2D). Cox multivariate analysis revealed that CDH1 high expression was an independent risk factor for a poor prognosis in BC patients (Figure 2E; \( P = 0.027 \)). Afterwards, the relationships between the mRNA expression of CDH1 and clinicopathologic features in BC are summarized in Table 1. High CDH1 expression was positively associated with Metastasis Status (\( P = 0.014 \)), ER (\( P = 0.019 \)), and PR (\( P = 0.003 \)) expressions. In addition, Malta et al. (36) used one-class logistic regression (OCLR) to generate a stemness index for evaluating the dedifferentiation degree of cancer and proposed a stemness index mRNA\( \text{asi} \) based on mRNA expression. The high value of mRNA\( \text{asi} \) was positively correlated with active biological processes in CSCs and tumor dedifferentiation. Therefore, we further evaluated the relationship between the stemness index and CDH1 expression in BC. The results showed that the CDH1 expression was significantly higher in high mRNA\( \text{asi} \) group than in low mRNA\( \text{asi} \) group of BC (Figure 2F), and high CDH1 expression was associated with higher mRNA\( \text{asi} \) (Figure 2G). Meanwhile, GSEA enrichment analysis revealed that CDH1 overexpression was positively correlated with stemness-related signatures (Figure 2H). These results suggest that CDH1 overexpression...
is positively associated with stemness in BC. CDH1 not only mediates the cancer progression but also serves as a risk factor and predictor of poor prognosis in BC.

Expression of miRNAs-Targeted CDH1 and Prognostic Significance

miRNAs have been identified as critical regulators of gene expression. As a result, we used Targetscan7, miRDB, microRNA, miRWalk, and starBase to predict potential miRNAs that regulate CDH1, and from Venn diagram, we obtained 24 miRNAs that may regulate CDH1 (Figure 3A). Through difference analysis and diagnostic efficiency (AUC ≥ 0.6) screening, eight significant differential expression miRNAs, respectively miR-340, miR-185, miR-20a, miR-5480, miR-4306, miR-510, miR-888, and miR-495 were identified (Figures 3B, C). Then, the expression degree of eight miRNAs regulating CDH1 was analyzed in BC tissues from normal tissues. (G) GEPIA database analysis of CDH1 expression was increased in all subtypes of BC tissues compared to normal tissue. (G) TCGA database shows higher levels of CDH1 expression in BC tissues than in per carcinomatous tissues. (H) HPA database shows higher expression of E-cadherin in BC tissues than in normal tissues. (I) Representative immunohistochemical staining of E-cadherin in multiple BC subtypes. Scale bar = 60μm (upper panels), Scale bar = 30μm (lower panels). * P < 0.05; ** P < 0.01; *** P < 0.001.
Correlated with poor OS in BC patients \[HR = 0.56, P = 0.041\]. High expression of miR-20a was correlated with poor OS in BC patients \[HR = 1.7, P = 0.048\] (Figure 3E).

**Correlation Between miR-340, miR-185 and miR-20a and Stemness Features of BC**

We performed expression analysis and enrichment analysis to explore the relationship between the expressions of miR-340, miR-185, miR-20a, and the stemness features of BC. The results showed no differences in the expression of miR-340 between the high mRNAsi group and the low mRNAsi group in BC (Figure 4A), and no association between miR-340 expression and mRNAsi (Figure 4B). The enrichment analysis indicated that miR-340 expression had no significant correlation with the stemness characteristics in BC (Figure 4C). The expressions of miR-185 and miR-20a in the high mRNAsi group of BC were significantly higher than those in the low mRNAsi group (Figures 4D, G). However, we found that only an association of high miR-20a expression with higher mRNAsi (Figure 4H), whereas miR-185 expression was not correlated with mRNAsi (Figure 4E). The enrichment analysis also revealed that the increased expressions of miR-185 and miR-20a were positively correlated with the stemness characteristics of BC (Figures 4F, I). These findings show that the overexpression of miR-185 and miR-20a, which target CDH1, promotes the stemness characteristics and is also linked to the malignant progression of BC.

**Functional Enrichment Analysis of CDH1 Combination With miR-340, miR-185, miR-20a**

To investigate the biological functions and regulatory mechanisms of CDH1 in combination with miR-340, miR-185, or miR-20a in BC, we performed functional enrichment analysis in the TCGA BC samples. GO enrichment analysis showed that
CDH1 overexpression combined with miR-340 was highly enriched in ubiquitin-like protein binding, ubiquitin binding, nucleotide transmembrane transporter activity, organophosphate ester transmembrane transporter activity, and DNA polymerase activity. On the other hand, the high expression of CDH1 in combination with miR-185 is over-increased in ubiquitin-like protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, pyrophosphate hydrolysis-driven proton transmembrane transporter activity, and carbohydrate kinase activity. The high expression of CDH1 in combination with miR-20a is highly enriched in histone methyltransferase activity, RNA involved in post-transcriptional gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activity, pyrophosphate hydrolysis—protein binding, ubiquitin-binding, ATPase coupled ion transmembrane transporter activity, and stem cells U6 SNRNA gene silencing, LRR domain binding, neurotransmitter transporter activi...
metastatic progression of numerous cancers (41–43). However, a small number of published studies have demonstrated that CDH1 has the pro-oncogenic activity. CDH1 upregulation can maintain the stemness characteristics of tumor cells and promote oncogenesis and progression (8, 13). In addition, many miRNAs participate in regulating cancer stem cells characteristics and they play an important role in the diagnosis and prognosis of tumors as new, easily accessible, affordable, non-invasive biomarker (45). Prior to this study, the oncogenic activity and clinical significance of CDH1 and its related miRNAs in regulating BC function have not been thoroughly investigated and established. This study has made the following novel findings:

First, bioinformatic analysis of publicly available cancer databases (including TIMER 2.0, GEPIA, Oncomine, TCGA, GEO, HPA, and Kaplan-Meier plotter) revealed that highly expressed CDH1 functions as an oncogene in BC and is positively correlated with malignancy progression (Figures 1, 2). Early studies suggest that CDH1, as a tumor suppressor gene, as evidenced by mutations or methylation of CDH1, silences CDH1 expression, thus increasing the incidence of BC, as well as infiltrative tumor growth and metastasis (46, 47). However, in the present study, CDH1 expression was found to be elevated in all BC subtypes, and CDH1 upregulation was positively related to BC patient stage, metastatic, poor prognosis, and stemness signature. The findings of our study
suggest that CDH1 may play an oncogene role in tumorigenesis and development of BC. Meanwhile, CDH1 has been reported to be a stemness gene. Increased CDH1 expression in embryonic stem cells contributes to pluripotency maintenance and prevents cell differentiation (48). Ye et al. (13) demonstrated that CDH1 is essential for the self-renewal of lung cancer stem-like cells. These findings uncovered a novel mechanism understanding by which high CDH1 expression may act as an oncogene by regulating tumor stemness characteristics. However, further in-depth mechanistic characterization will answer whether CDH1 is a novel target for therapeutic development.

Second, miRNA target gene prediction and analysis revealed that enhanced miR-340, miR-185, and miR-20a could target CDH1 in BC. Among them, miR-20a overexpression was positively linked to the stemness characteristics and poor prognosis of BC, which might be the pro-oncogene associated with stemness progression of breast cancer. In fact, miR-340 has been widely reported as a tumor suppressor (49). In BC, miR-340 overexpression was shown to significantly inhibit BC cell migration and invasion (50, 51). However, our study discovered that, despite being highly expressed in BC, miR-340 did not correlate with either stemness characteristics or prognosis of BC. Low expressed miR-185 has been reported to contribute to the acquisition of stemness characteristics in BC cells when regulated by LINC00511 (52), as opposed to our prediction that high expression of miR-185 is positively

FIGURE 4 | Correlation analysis between miR-340, miR-185, and miR-20a and stemness signature of breast cancer. (A, D, G) TCGA database analysis of miR-340, miR-185 and miR-20a expression differences in BC mRNAs high and low groups. (B, E, H) Association analysis between miR-340, miR-185 and miR-20a expression and mRNAs in BC. (C, F, I) GSEA assessment of the enrichment score profile of miR-340, miR-185, and miR-20a expression in the stemness high and low groups. *P < 0.05; **P < 0.001.
associated with stemness characteristics in BC. The discrepancies exist between our findings and those on miR-340 and miR-185 as a tumor suppressor. More research is required to determine their role in BC progression. Furthermore, high miR-20a expression was positively associated with both stemness features and the poor prognosis of BC. miR-20a has been widely reported as an oncogenic miRNA, which confirms our prediction. In BC, miR-20a could promotes the proliferation and invasion of BC cells by targeting ZBTB4 or PTEN (53, 54). In addition, high expression of miR-20a upregulates the self-renewal and proliferation of gastric cancer stem cells and is positively correlated with the poor prognosis of gastric cancer (55, 56). It implies that miR-20a acts as an oncogenic molecule in BC and may contribute to malignant progression and poor prognosis by promoting tumor

FIGURE 5 | Enrichment analysis of CDH1 in combination with miR-340, miR-185, or miR-20a. (A) Gene Ontology functions enrichment analysis. (B) Hallmark gene set enrichment analysis. (C) KEGG pathways enrichment analysis.

To better understand the biogenesis of miR-20a regulated, we further investigate all the targets of miR-20a other than CDH1, and implemented HALLMARK, KEGG, GO enrichment to discovery the functions in which the miR-20a participated in the tumorigenesis and development (Supplement 1). Notably, the possible relation of miR-340, miR-185, and miR-20a to CDH1 and how miRNA regulates stemness in BC should be further revealed by experimental evidence.

Third, using bioinformatics analysis, this study innovatively predicted the potential signaling pathways underlying the oncogenic activity of high expression of CDH1 in combination with overexpression of miR-340, miR-185, or miR-20 in BC. Of these, GO, and GSEA enrichment analyses showed that miR-340 or miR-185 combined with CDH1 overexpression existed in
common enrichment pathways, such as glycolysis, MTORC1 signaling, steroid biosynthesis, peroxidase, and ubiquitination binding, which are closely related to cancer cell metabolism. It is well known that altered metabolism is one of the hallmarks of cancer. Numerous cancer cells rely on aerobic glycolysis for nutrients and energy (57). The activation of SREBP1 by mTORC1 in BC cells inhibits adipogenesis and interferes with cancer cell proliferation and tumor growth (58). Additionally, BC is a malignancy in which steroid hormones drive cellular proliferation, such as the sex steroid hormones estrogen receptor (ER) and progesterone receptor (PR), which are important prognostic and predictive markers for BC (59). Although miR-340 and miR-185 have been reported as tumor suppressor miRNAs, the mechanism by which miR-340 and miR-185 targeting CDH1 has not been investigated, and further studies are required to determine the oncogenic regulatory mechanism. Of note, CDH1 co-overexpression in combination with miR-20a was highly enriched mainly in histone methyltransferase activity, MYC targets V2, WNT/BETA-CATENIN signaling and ribosomes. Among them, MYC and WNT/BETA-CATENIN signaling pathways are important regulatory pathways for cancer stem cell self-renewal (4, 60). Recent studies have reported that histone methyltransferase EZH2 plays a critical role in maintaining ovarian CSC stemness (61). Glioma cells acquire stem-like characters by extrinsic ribosome stimuli (62). This indicates that the potential oncogenic mechanism of miR-20a-targeted regulation of CDH1 may be intricately linked with the stemness progression of BC, which warrants further investigation.

Fourth, we provide convincing experimental evidence supporting that sE-cad, which is formed by the secretion of CDH1-encoded E-cad into serum and combined with miR-20a, serves as a diagnostic marker for BC (A–C). The ROC curves for the diagnostic value of the CDH1, miR-340, miR-185, and miR-20a in BC (D–G). Serum miR-340, miR-185, miR-20a, and sE-cad expression levels in BC patients and healthy subjects. (H) sE-cad in serum levels of BC patients at different stages. (I) ROC curves of sE-cad in combination with miR-20a diagnostic model. *P < 0.05; **P < 0.01; ***P < 0.001. no significant difference.

FIGURE 6 | The diagnostic significances of sE-cad and miR-340, miR-185, miR-20a in BC. (A–C) The ROC curves for the diagnostic value of the CDH1, miR-340, miR-185, and miR-20a in BC. (D–G) Serum miR-340, miR-185, miR-20a, and sE-cad expression levels in BC patients and healthy subjects. (H) sE-cad in serum levels of BC patients at different stages. (I) ROC curves of sE-cad in combination with miR-20a diagnostic model. *P < 0.05; **P < 0.01; ***P < 0.001. no significant difference.
20a detection, has better diagnostic potential in BC. In a recent study, the screening for biomarkers associated with cancer stem cell signatures provided novel insights into the selection of tumor diagnostic biomarkers (36, 63). Consequently, we further explored the potential of CDH1 and miR-340, miR-185 and miR-20a as non-invasive diagnostic markers for BC patients. Our results show that sE-cad was significantly highly expressed in the sera of BC patients and positively related to the BC stage and lymphoid nodal status, consistent with bioinformatics analysis results that CDH1 overexpression was positively linked to malignant progression of BC. According to literature, miR-20a has a good diagnostic value in colorectal cancer (AUC=0.70) (64). Our study showed that miR-20a had comparatively good diagnostic potential in BC, with an AUC of 0.807. Furthermore, sE-cad combined with miR-20a assay improved BC diagnostic efficiency with an AUC of 0.903.

In conclusion, this study provides evidence for CDH1 as an oncogene in BC and suggests that miR-20a may regulate the stemness characteristics of BC to exert a pro-oncogenic effect by regulating CDH1. Simultaneously, sE-cad and miR-20a in serum can both be used as valid noninvasive markers for BC diagnosis. Therefore, these results demonstrate the potential of CDH1 and its related miRNAs as new clinical targets for the diagnosis, prognosis and treatment of BC which will be explored in our future studies.

### DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

### ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethical Committee of the Affiliated Hospital of Southwest Medical University. The patients/participants provided their written informed consent to participate in this study.

### AUTHOR CONTRIBUTIONS

The concept and design of the present study were mainly provided by TY. DX, YC, and XW contributed to drafting and editing the manuscript. Experiment data were collected and analyzed by QP, DX, and YL. JYL, JBL, YC, and XW performed the data acquisition and data analysis. Finally, TY conducted data auditing and manuscript review. All authors contributed to the article and approved the submitted version.
FUNDING
This work was supported by the National Natural Science Youth Fund, China (Grant No.82003138), the Sichuan Science and Technology Program for key Research and Development, China (Grant No.2021YSF0226), Scientific and technology strategic cooperation project of Luzhou People’s Government and Southwest Medical University (Grant No.2021LZXNYD-J08), Doctoral Research Initiation Fund of Affiliated Hospital of Southwest Medical University, China (Grant No.19077) and University’s scientific research project of Southwest Medical University, China (Grant No. 20202RQNA019).

REFERENCES
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3332/caac.221660
2. Winters S, Martin C, Murphy D, Shokar NK. Breast Cancer Epidemiology, Prevention, and Screening. Prog Mol Biol Transl Sci (2017) 151:1–32. doi: 10.1016/bs.pmbts.2017.07.002
3. Jin X, Zha L, Xiao S, Cui Z, Tang J, Yu J, et al. MST1 Inhibits the Progression of Breast Cancer by Regulating the Hippo Signaling Pathway and may Serve as a Prognostic Biomarker. Mol Med Rep (2021) 23(5):383. doi: 10.3892/mmr.2021.12022
4. Yang Y, Li X, Wang T, Guo Q, Xi T, Zheng L. Emerging Agents That Target Signaling Pathways in Cancer Stem Cells. J Hematol Oncol (2020) 13(1):60. doi: 10.1186/s13045-020-00901-6
5. Xie D, Pei Q, Li J, Wan X, Ye T. Emerging Role of EZF Family in Cancer Stem Cells. Front Oncol. Front Oncol (2021) 11:723137. doi: 10.3389/fonc.2021.723137
6. Söninc F, Ward CM. The Function of E-Cadherin in Stem Cell Pluripotency and Self-Renewal. Genes (Basel) (2011) 2(1):229–59. doi: 10.3390/genes20100229
7. Karpowicz P, Willaime-Morawek S, Balenci L, Deveale B, Inoue T, van der Kooy D. E-Cadherin Regulates Neural Stem Cell Self-Renewal. J Neurosci (2009) 29(12):3885–96. doi: 10.1523/jneurosci.0307-09.2009
8. Redmer T, Diecke S, Grigoryan T, Quiroga-Negreira A, Birchmeier W, Besser D. E-Cadherin is Crucial for Embryonic Stem Cell Pluripotency and can Replace OCT4 During Somatic Cell Reprogramming. EMBO Rep (2011) 12(7):720–6. doi: 10.1038/embr.2011.88
9. Berx G, Becker KF, Höffer H, Van Roy F. Mutations of the Human E-Cadherin (CDH1) Gene. Hum Mutat (1998) 12(4):226–37. doi: 10.1002/(sici)1098-1099(1998)12:4<226::aid-humu2>3.0.co;2-d
10. Richards FM, Mckee SA, Frye C, Mccellain S, Allan RW, Andrejewski JT, et al. Expression of Pluripotent Stem Cell Reprogramming Factors by Prostate Tumor Initiating Cells. J Urol (2010) 183(5):2045–53. doi: 10.1016/j.juro.2009.12.092
11. Gogali A, Charalabopoulos K, Zampira I, Konstantinidis AK, Tachmazoglou I, Daskalopoulos G, et al. Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma. Sci Rep (2019) 9(1):10464. doi: 10.1038/s41598-019-46872-8
12. Conti I, Simion C, Varano G, Brenna C, Costanzi E, Neri LM. MicroRNAs Patterns as Potential Tools for Diagnostic and Prognostic Follow-Up in Cancer Survivorship. Cells (2021) 10(8):2069. doi: 10.3390/cells10082069
13. Liu H, Bian QZ, Zhang W, Cui HB. Circulating microRNA-103a-3p Could be a Diagnostic and Prognostic Biomarker for Breast Cancer. Oncol Lett (2022) 21(3):182. doi: 10.3892/ol.2022.13156
14. Huang X, Yuan T, Liang M, Xia S, Dittmar R, et al. Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-Resistant Prostate Cancer. Eur Urol (2015) 67(1):33–41. doi: 10.1016/j.eururo.2014.07.035
15. Rhodes DR, Yu J, Shanker K, Deshpande V, Varambally R, Ghosh D, et al. ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia (2004) (2004) 6(1):1–6. doi: 10.1378/chest.10-0157
16. Karpowicz P, Willaime-Morawek S, Balenci L, Deveale B, Inoue T, van der Kooy D. E-Cadherin Regulates Neural Stem Cell Self-Renewal. J Neurosci (2009) 29(12):3885–96. doi: 10.1523/jneurosci.0307-09.2009
17. Padmanaban V, Krol I, Suhail Y, Szczersa BM, Aceto N, Bader JS, et al. E-Cadherin is Required for Metastasis in Multiple Models of Breast Cancer. Nature (2019) 573(7749):439–44. doi: 10.1038/s41586-019-1526-3
18. Wheelock MJ, Buck CA, Bechtol KB, Damsky CH. Soluble 80-Kd Fragment of Cadherin is Correlated With Clinicopathological Features and Prognosis of Breast Cancer. Med Sci Monit (2017) 23:4016–22. doi: 10.12659/msm.902409
19. Chen L, Heikinien L, Wang C, Yang Y, Sun H, Wong G. Trends in the Development of miRNA Bioinformatics Tools. Brief Bioinform (2019) 20(5):1836–52. doi: 10.1093/bib/bby054
20. Ali Syeda Z, Langden SSS, Munkhzul C, Lee M, Song SJ. Regulatory Mechanism of MicroRNA Expression in Cancer. Int J Mol Sci (2020) 21(5):1723. doi: 10.3390/ijms21051723
21. Jin Y, Wong YS, Goh BKP, Chan CY, Cheow PC, Chow PKH, et al. Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma. Sci Rep (2019) 9(1):10464. doi: 10.1038/s41598-019-46872-8
22. Conti I, Simion C, Varano G, Brenna C, Costanzi E, Neri LM. MicroRNAs Patterns as Potential Tools for Diagnostic and Prognostic Follow-Up in Cancer Survivorship. Cells (2021) 10(8):2069. doi: 10.3390/cells10082069
23. Liu H, Bian QZ, Zhang W, Cui HB. Circulating microRNA-103a-3p Could be a Diagnostic and Prognostic Biomarker for Breast Cancer. Oncol Lett (2022) 21(3):182. doi: 10.3892/ol.2022.13156
24. Huang X, Yuan T, Liang M, Xia S, Dittmar R, et al. Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-Resistant Prostate Cancer. Eur Urol (2015) 67(1):33–41. doi: 10.1016/j.eururo.2014.07.035
25. Rhodes DR, Yu J, Shanker K, Deshpande V, Varambally R, Ghosh D, et al. ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform. Neoplasia (2004) (2004) 6(1):1–6. doi: 10.1378/chest.10-0157
26. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for Analysis of Tumor-Infiltrating Immune Cells. Nucleic Acids Res (2020) 48(W1):W309–14. doi: 10.1093/nar/gkaa407
31. Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-Analyzed Tumors. Cell (2018) 173(2):530. doi: 10.1016/j.cell.2018.03.059

32. Barl M, Willhite SE, Ledoux P, Evangelista C, Kim JF, Tomashovsky M, et al. NCI-T: Archive for Functional Genomics Data Sets—Update. Nucleic Acids Res (2013) 41(Database issue):D995–5. doi: 10.1093/nar/gkt4193

33. Tang Z, Li, Kang B, Gao G, Li C, Zhang Z. GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Res (2017) 45(W1):W98–W102. doi: 10.1093/nar/gkx247

34. Thul PJ, Lindsgaard C. The Human Protein Atlas: A Spatial Map of the Human Proteome. Protein Sci (2018) 27(1):233–44. doi: 10.1002/pro.3307

35. Lanczky A, Gyorffy B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMPilot): Development and Implementation. J Med Internet Res (2021) 23(7):e27633. doi: 10.2196/27633

36. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine Learning Identifies Stemness Features Associated With Oncogenic Dedifferentiation. Cell (2018) 173(2):338–54.e15. doi: 10.1016/j.cell.2018.03.034

37. Powers RK, Goodspeed A, Pielke-Lombardo H, Tan AC, Costello JC. GSEA-InContext: Identifying Novel and Common Patterns in Expression Experiments. Bioinformatics (2018) 34(13):555–64. doi: 10.1093/bioinformatics/bty271

38. Zhang SJ, Hu Y, Qian HL, Jiao SC, Liu ZF, Tao HT, et al. Expression and Functional Analysis of CDH1 in breast cancer cells. J Cell Sci (2016) 119(2):291–9. doi: 10.1242/jcs.157347

39. Bao H, Yu D, Wang J, Qiu T, Yang J, Wang L. Predictive Value of Serum Anti-P53 Antibodies, Carcino-Embryonic Antigen, Carbohydrate Antigen 15-3, Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor-2 in Taxane-Based and Anthracycline-Based Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. Anticancer Drugs (2008) 19(3):317–23. doi: 10.1080/09514230701648420

40. Pei J, Wang Y, Li Y. Identification of Key Genes Controlling Breast Cancer Stem Cell Characteristics via Stemness Indices Analysis. J Transl Med (2020) 18(1):74. doi: 10.1186/s12976-020-02260-9

41. Figueiredo J, Melo S, Carneiro P, Moreira AM, Fernandes MS, Ribeiro AS, et al. Clinical Spectrum and Pleiotropic Nature of CDH1 Germline Mutations. J Med Genet (2019) 56(4):199. doi: 10.1136/jmedgenet-2018-105807

42. Wu X, Yao C, Cao Q, Wu Z, Wang Z, Liu F, et al. Clinicopathological and Prognostic Significance of CDH1 Hypermethylation in Hepatocellular Carcinoma: A Meta-Analysis. Cancer Manag Res (2019) 11:857–64. doi: 10.2147/cmar.s179710

43. Kim SA, Inamura K, Yamauchi M, Nishihara R, Mima K, Sukawa Y, et al. Loss of CDH1 axis contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/ZEB1/ Nanog Axis. J Exp Clin Cancer Res (2018) 37(1):289. doi: 10.1186/s13046-018-0945-6

44. Xie et al. Roles of CDH1 in BC

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publishers, the editors or the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xie, Chen, Wan, Li, Pei, Luo, Liu and Ye. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright holder are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.